NCT05746728 2023-04-06Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerTongji HospitalPhase 1/2 Unknown45 enrolled
NCT05186545 2022-09-02An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast CancerThe First Affiliated Hospital of Zhengzhou UniversityPhase 2 Unknown63 enrolled